Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Oishi, K. Aoe, Y. Murata, K. Sakamoto, T. Ohfuji, W. Kotoku, Y. Ogata, T. Matsumoto, H. Ueoka, Y. Mimura (Ube, Japan). Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion. Eur Respir J 2013; 42: Suppl. 57, 462

Member's Comments

No comment yet.

Related content which might interest you: A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease Source: Eur Respir Rev 2009; 18: 129-132 Year: 2009 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Survival from acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with polymyxin B-immobilized fiber column: A retrospective analysis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Prognostic factors analysis of patients with rapid progressive interstitial pneumonias treated by direct hemoperfusion with polymyxin B-immobilized fiber column Source: International Congress 2014 – ILDs 1 Year: 2014 Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia Source: Eur Respir J 2002; 19: 1114-1118 Year: 2002 Survival after respiratory hospitalization in patients with idiopathic chronic fibrosing interstitial pneumonia Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias Source: Eur Respir Rev 2008; 17: 108-115 Year: 2008 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016